2013美國臨床內分泌醫(yī)師協(xié)會糖尿病專家共識
《2013美國臨床內分泌醫(yī)師協(xié)會糖尿病專家共識》內容簡介：
This document is organized into discrete sections thataddress the following topics: obesity, prediabetes, manage-ment of hyperglycemia through lifestyle modifications,pharmacotherapy and insulin, management of hyperten-sion, management of hyperlipidemia, and other risk-reduc-tion strategies.
《2013美國臨床內分泌醫(yī)師協(xié)會糖尿病專家共識》內容預覽：
Prediabetes reflects failing pancreatic compensationto an underlying state of insulin resistance, most com-monly caused by excess body weight or obesity. Currentcriteria for the diagnosis of prediabetes include impairedglucose tolerance, impaired fasting glucose, or metabolicsyndrome. （See Comprehensive Diabetes ManagementAlgorithm-Prediabetes Algorithm）。 Any one of these fac-tors is associated with a 5-fold increase in future T2DMrisk （12）。
The primary goal of prediabetes management isweight loss. Whether achieved through TLC, pharmaco-therapy, surgery, or some combination thereof, weight lossreduces insulin resistance and can effectively prevent pro-gression to diabetes as well as improve lipids and bloodpressure. However, weight loss may not directly addressthe pathogenesis of declining beta-cell function. Whenindicated, bariatric surgery can also be highly effective inpreventing progression to diabetes （12）。
點擊下載***：《2013美國臨床內分泌醫(yī)師協(xié)會糖尿病專家共識》
本站所注明來源為"愛愛醫(yī)"的文章，版權歸作者與本站共同所有，非經(jīng)授權不得轉載。
本站所有轉載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉載的媒體或個人可與我們
聯(lián)系zlzs@120.net，我們將立即進行刪除處理
